Evotec and Pfizer have entered a multi-year partnership focused on early discovery research targeting metabolic and infectious diseases. The collaboration, which includes a master research collaboration and option and licence agreement, will see research activities conducted at Evotec's facilities in France, particularly the advanced Campus Curie research site in Toulouse. This site is well-equipped with high throughput screening capacity, in vitro and in vivo biology, metabolomics, and proteomics.
Evotec's chief business officer, Dr. Matthias Evers, expressed enthusiasm about the collaboration, emphasizing the focus on diseases with severe unmet medical needs and innovative therapeutic approaches. The partnership aims to support Pfizer with integrated research and development activities, benefitting from Pfizer's research support funding. Evotec may also receive potential milestones and royalty payments contingent on the success of the programs.
Dr. Luca Mollo, Pfizer France vice-president and medical lead, highlighted the importance of the collaboration in advancing scientific discovery for diseases with significant unmet needs. He noted the strength of France's biopharmaceutical ecosystem as a key factor in choosing to partner with Evotec.
In addition to this partnership, Evotec has recently teamed up with Variant Bio to develop treatments for ailments caused by fibrosis. This alliance will combine Variant Bio's genomic discovery expertise and VB-Inference platform with Evotec's antifibrotic drug discovery capabilities, further showcasing Evotec's commitment to addressing challenging medical conditions.
Click here to read the original news story.